ysynut.wordpress.com
The Rockville-based company’s BioThrax has been granted a shelf life extensionh from the from its current thred yearsto four. Under its contract with the Department of Healtg andHuman Services, the extension trigger a milestone payment of $30 million for dose s of the vaccine already delivered to the Strategix National Stockpile. Emergent expectas to record that payment as revenuethis quarter. The shelf life extensiohn also allows Emergent to charge more for futurr doses of the vaccine delivered tothe government’a stockpile. That could raise the value of the contract to as muchas $405 million over the next severall years.
Last year, the FDA approved a reduced vaccinatiom schedule tofive doses. Emergent continuezs research that could lead to a furthe r reduction in the number ofdoses required, as well as the vaccine’ws use to treat patientws after being exposed to Anthrax, not just as a pre-exposures vaccine. Emergent has supplied the government’e stockpile with 33 million doses of BioThraxso far. It is contractede to continue adding to stockpiles throughlate 2011. BioThradx has been used to vaccinate more than 2 millionm military personnel since the government firstg started buying the vaccinein 1998. Emergen stock (NYSE: EBS) was up 90 cents to $14.633 per share in afternoon trading.
No comments:
Post a Comment